NO20064262L - Fast formulering av ospemifen - Google Patents
Fast formulering av ospemifenInfo
- Publication number
- NO20064262L NO20064262L NO20064262A NO20064262A NO20064262L NO 20064262 L NO20064262 L NO 20064262L NO 20064262 A NO20064262 A NO 20064262A NO 20064262 A NO20064262 A NO 20064262A NO 20064262 L NO20064262 L NO 20064262L
- Authority
- NO
- Norway
- Prior art keywords
- ospemifene
- solid formulation
- deaminohydroxy
- toremifene
- stereoisomer
- Prior art date
Links
- LUMKNAVTFCDUIE-VHXPQNKSSA-N ospemifene Chemical compound C1=CC(OCCO)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 LUMKNAVTFCDUIE-VHXPQNKSSA-N 0.000 title abstract 3
- 229960003969 ospemifene Drugs 0.000 title abstract 2
- 239000007787 solid Substances 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000013583 drug formulation Substances 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 239000008187 granular material Substances 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Foreliggende oppfinnelse vedrører faste medikamentformuleringer omfattende granulater inneholdende ospemifen (også kjent som (deaminohydroksy)toremifen) som en terapeutisk aktiv forbindelse, eller en geometrisk isomer, en stereoisomer, et farmasøytisk akseptabelt salt, en ester derav eller en metabolitt derav, i kombinasjon med én eller flere intra-granulære eksepienser.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/783,024 US8642079B2 (en) | 2004-02-23 | 2004-02-23 | Solid formulations of ospemifene |
PCT/FI2005/000037 WO2005079777A1 (en) | 2004-02-23 | 2005-01-19 | Solid formulations of ospemifene |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20064262L true NO20064262L (no) | 2006-09-20 |
NO341573B1 NO341573B1 (no) | 2017-12-04 |
Family
ID=34861126
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20064262A NO341573B1 (no) | 2004-02-23 | 2006-09-20 | Faste formuleringer av ospemifen og fremgangsmåte for fremstilling av ospemifen |
Country Status (19)
Country | Link |
---|---|
US (2) | US8642079B2 (no) |
EP (2) | EP2286806A1 (no) |
JP (1) | JP4993203B2 (no) |
CN (1) | CN1953741B (no) |
AT (1) | ATE506054T1 (no) |
AU (1) | AU2005215174B2 (no) |
BR (1) | BRPI0507897B8 (no) |
CA (1) | CA2554695C (no) |
CY (1) | CY1111689T1 (no) |
DE (1) | DE602005027540D1 (no) |
DK (1) | DK1718288T3 (no) |
ES (1) | ES2364970T3 (no) |
MX (1) | MXPA06009546A (no) |
NO (1) | NO341573B1 (no) |
PL (1) | PL1718288T3 (no) |
PT (1) | PT1718288E (no) |
RU (2) | RU2675624C2 (no) |
SI (1) | SI1718288T1 (no) |
WO (1) | WO2005079777A1 (no) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60234812D1 (de) | 2001-01-29 | 2010-02-04 | Shionogi & Co | Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält |
US8236861B2 (en) | 2004-02-13 | 2012-08-07 | Hormos Medical Corporation | Method for enhancing the bioavailablity of ospemifene |
US8642079B2 (en) | 2004-02-23 | 2014-02-04 | Hormos Medical Corporation | Solid formulations of ospemifene |
DK2275098T3 (da) | 2004-05-04 | 2012-08-20 | Hormos Medical Ltd | Hidtil ukendte orale formulationer af ospemifen |
US8758821B2 (en) * | 2004-05-04 | 2014-06-24 | Hormos Medical Ltd. | Oral formulations of ospemifene |
NZ591443A (en) * | 2005-09-22 | 2013-04-26 | Intermune Inc | Granule formation of pirfenidone and pharmaceutically acceptable excipients |
CA2628964A1 (en) * | 2005-11-09 | 2007-09-07 | Hormos Medical Ltd. | Formulations of fispemifene |
CA2563690C (en) * | 2006-10-12 | 2014-10-07 | Pharmascience Inc. | Pharmaceutical compositions comprising intra- and extra- granular fractions |
WO2008099060A2 (en) | 2007-02-14 | 2008-08-21 | Hormos Medical Ltd | Methods for the preparation of fispemifene from ospemifene |
ES2524002T3 (es) | 2007-02-14 | 2014-12-03 | Forendo Pharma Ltd. | Método para la preparación de derivados de trifenilbuteno con valor terapéutico |
WO2009123626A1 (en) * | 2008-04-01 | 2009-10-08 | Ocean 1 806, Llc | Orodispersable formulations of phosphodiesterase-5 (pde-5) inhibitors |
JP6174156B2 (ja) | 2012-10-19 | 2017-08-02 | フェルミオン オサケ ユキチュア | オスペミフェンの製造方法 |
CN104788300B (zh) * | 2014-01-22 | 2017-01-11 | 南京华威医药科技开发有限公司 | 欧司哌米芬多晶型 |
US20160000732A1 (en) * | 2014-07-02 | 2016-01-07 | Cadila Healthcare Limited | Oral pharmaceutical compositions of ospemifene |
US20160022604A1 (en) * | 2014-07-23 | 2016-01-28 | Cadila Healthcare Limited | Directly compressed ospemifene compositions |
US10138190B2 (en) | 2015-01-09 | 2018-11-27 | Glenmark Pharmaceuticals Limited | Process for preparation of ospemifene |
CA2976811C (en) * | 2015-03-10 | 2023-06-27 | Shionogi Inc. | Solid dispersions of ospemifene |
CA2937365C (en) | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
MX2019008506A (es) * | 2017-01-24 | 2019-10-30 | Omnigen Res L L C | Suplemento de alimento granulado y metodos para elaboracion y uso. |
JP2023526098A (ja) | 2020-05-18 | 2023-06-20 | オレクソ・アクチエボラゲット | 薬物送達のための新しい医薬組成物 |
WO2023094826A1 (en) | 2021-11-25 | 2023-06-01 | Orexo Ab | Pharmaceutical composition comprising adrenaline |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4117121A (en) | 1977-04-22 | 1978-09-26 | Hoffmann-La Roche Inc. | Method of increasing bile flow and decreasing lipid levels |
FI100692B (fi) | 1994-05-24 | 1998-02-13 | Leiras Oy | Menetelmä farmaseuttisten koostumusten valmistamiseksi, jolloin koostu mukset pohjautuvat mikroemulsiogeeleihin sekä uusia mikroemulsioihin p ohjautuvia geelejä |
GB9418067D0 (en) | 1994-09-07 | 1994-10-26 | Orion Yhtymae Oy | Triphenylethylenes for the prevention and treatment of osteoporosis |
US6562862B1 (en) | 1994-10-20 | 2003-05-13 | Eli Lilly And Company | Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y |
US5597582A (en) | 1995-09-12 | 1997-01-28 | Sanofi | Oral gel capsule formulation of 1,2,4-benzotriazine oxides |
AU718417B2 (en) * | 1995-11-14 | 2000-04-13 | Stockhausen Gmbh & Co. Kg | Water additive and method for fire prevention and fire extinguishing |
GB9604577D0 (en) | 1996-03-04 | 1996-05-01 | Orion Yhtymae Oy | Serum cholesterol lowering agent |
FI101305B (fi) | 1996-03-18 | 1998-05-29 | Map Medical Technologies Oy | Radiofarmaseuttisena aineena käyttökelpoiset radiojodatut bentsodiatse piini-johdannaiset ja niiden käyttö diagnostiikassa |
DE19653736C2 (de) * | 1996-12-12 | 2002-11-21 | Lancaster Group Gmbh | Kosmetisches Präparat mit Peptidzusatz |
RU2112504C1 (ru) * | 1996-12-24 | 1998-06-10 | Открытое акционерное общество "Нижегородский химико-фармацевтический завод" | Средство для лечения заболеваний предстательной железы "витапрост" |
US6525084B2 (en) * | 1998-07-23 | 2003-02-25 | Novo Nordisk A/S | Stable pharmaceutical formulation |
JP2002521322A (ja) * | 1998-07-23 | 2002-07-16 | ノボ ノルディスク アクティーゼルスカブ | 安定な医薬製剤の製造のための湿式顆粒化方法 |
US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6245352B1 (en) | 1999-04-27 | 2001-06-12 | Eli Lilly And Company | Pharmaceutical formulation |
US6245819B1 (en) | 2000-07-21 | 2001-06-12 | Hormos Medical Oy, Ltd. | Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause |
US6838484B2 (en) * | 2000-08-24 | 2005-01-04 | University Of Tennessee Research Foundation | Formulations comprising selective androgen receptor modulators |
WO2002056903A2 (en) | 2001-01-17 | 2002-07-25 | Praecis Pharmaceuticals Inc. | Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators |
RU2177802C1 (ru) * | 2001-01-25 | 2002-01-10 | Санкт-Петербургская Общественная Организация "Санкт-Петербургский Институт Биорегуляции И Геронтологии Сзо Рамн" | Тетрапептид, регулирующий функции предстательной железы, фармакологическое средство на его основе и способ его применения |
US20030055075A1 (en) * | 2001-07-13 | 2003-03-20 | Rubsamen Reid M. | Programmable controlled release injectable opioid formulation |
CA2458452C (en) * | 2001-08-10 | 2011-04-19 | Takeda Chemical Industries, Ltd. | Gnrh agonist combination drugs |
HUP0202719A3 (en) | 2001-08-21 | 2006-01-30 | Pfizer Prod Inc | Pharmaceutical compositions for the treatment of female sexual dysfunctions |
ATE344025T1 (de) | 2002-06-06 | 2006-11-15 | Hormos Medical Ltd | Behandlung oder prävention von urogenitaler atrophie und deren symptomen bei frauen |
US7407965B2 (en) | 2003-04-25 | 2008-08-05 | Gilead Sciences, Inc. | Phosphonate analogs for treating metabolic diseases |
US8236861B2 (en) * | 2004-02-13 | 2012-08-07 | Hormos Medical Corporation | Method for enhancing the bioavailablity of ospemifene |
US8642079B2 (en) | 2004-02-23 | 2014-02-04 | Hormos Medical Corporation | Solid formulations of ospemifene |
WO2006052921A2 (en) | 2004-11-08 | 2006-05-18 | Eastman Chemical Company | Cyclodextrin solubilizers for liquid and semi-solid formulations |
EA200700760A1 (ru) * | 2007-04-27 | 2008-08-29 | Открытое Акционерное Общество "Нижегородский Химико-Фармацевтический Завод" (Оао "Нижфарм") | Средство для лечения заболеваний предстательной железы |
RU2430733C2 (ru) * | 2009-10-08 | 2011-10-10 | Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") | Фармацевтическая композиция для лечения заболеваний предстательной железы (варианты) |
-
2004
- 2004-02-23 US US10/783,024 patent/US8642079B2/en active Active
-
2005
- 2005-01-19 CA CA2554695A patent/CA2554695C/en active Active
- 2005-01-19 DE DE602005027540T patent/DE602005027540D1/de active Active
- 2005-01-19 PT PT05708125T patent/PT1718288E/pt unknown
- 2005-01-19 CN CN2005800049727A patent/CN1953741B/zh active Active
- 2005-01-19 JP JP2007500233A patent/JP4993203B2/ja active Active
- 2005-01-19 RU RU2011112362A patent/RU2675624C2/ru not_active Application Discontinuation
- 2005-01-19 AU AU2005215174A patent/AU2005215174B2/en active Active
- 2005-01-19 EP EP10180718A patent/EP2286806A1/en not_active Withdrawn
- 2005-01-19 AT AT05708125T patent/ATE506054T1/de active
- 2005-01-19 DK DK05708125.9T patent/DK1718288T3/da active
- 2005-01-19 WO PCT/FI2005/000037 patent/WO2005079777A1/en active Application Filing
- 2005-01-19 EP EP05708125A patent/EP1718288B1/en active Active
- 2005-01-19 PL PL05708125T patent/PL1718288T3/pl unknown
- 2005-01-19 RU RU2006133902/15A patent/RU2423113C2/ru active
- 2005-01-19 ES ES05708125T patent/ES2364970T3/es active Active
- 2005-01-19 MX MXPA06009546A patent/MXPA06009546A/es active IP Right Grant
- 2005-01-19 BR BRPI0507897A patent/BRPI0507897B8/pt not_active IP Right Cessation
- 2005-01-19 SI SI200531330T patent/SI1718288T1/sl unknown
-
2006
- 2006-09-20 NO NO20064262A patent/NO341573B1/no unknown
-
2011
- 2011-07-14 CY CY20111100689T patent/CY1111689T1/el unknown
-
2014
- 2014-01-30 US US14/168,842 patent/US20140220118A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US8642079B2 (en) | 2014-02-04 |
PT1718288E (pt) | 2011-07-25 |
RU2423113C2 (ru) | 2011-07-10 |
PL1718288T3 (pl) | 2011-10-31 |
MXPA06009546A (es) | 2007-04-10 |
CN1953741B (zh) | 2011-03-30 |
AU2005215174A1 (en) | 2005-09-01 |
US20140220118A1 (en) | 2014-08-07 |
EP2286806A1 (en) | 2011-02-23 |
CN1953741A (zh) | 2007-04-25 |
AU2005215174B2 (en) | 2010-06-03 |
RU2006133902A (ru) | 2008-03-27 |
CA2554695A1 (en) | 2005-09-01 |
BRPI0507897A (pt) | 2007-07-24 |
JP2007523210A (ja) | 2007-08-16 |
NO341573B1 (no) | 2017-12-04 |
CY1111689T1 (el) | 2015-10-07 |
DK1718288T3 (da) | 2011-08-01 |
RU2011112362A (ru) | 2012-10-10 |
BRPI0507897B1 (pt) | 2018-10-09 |
SI1718288T1 (sl) | 2011-09-30 |
US20050187301A1 (en) | 2005-08-25 |
DE602005027540D1 (de) | 2011-06-01 |
EP1718288B1 (en) | 2011-04-20 |
ES2364970T3 (es) | 2011-09-19 |
BRPI0507897B8 (pt) | 2021-05-25 |
RU2675624C2 (ru) | 2018-12-21 |
WO2005079777A1 (en) | 2005-09-01 |
EP1718288A1 (en) | 2006-11-08 |
ATE506054T1 (de) | 2011-05-15 |
JP4993203B2 (ja) | 2012-08-08 |
CA2554695C (en) | 2013-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20064262L (no) | Fast formulering av ospemifen | |
NO20080220L (no) | Formuleringer med hoy medikament belastning og doseringsformer | |
MX2009013832A (es) | Derivados de purina y su uso como moduladores del receptor 7 similar a un puente. | |
HUS1500030I1 (hu) | Eljárás az ospemifene biohasznosulásának javítására | |
NO20074295L (no) | Substituerte gamma lactamer som terapeutiske midler | |
WO2008146178A3 (en) | A novel tablet dosage form | |
CY1119817T1 (el) | Στερεα μοναδα δοσολογιας διασπωμενη στο στομα που περιεχει συστατικο οιστετρολης | |
NO20082181L (no) | Formuleringer av Fispemifen | |
AR055099A1 (es) | Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol | |
NO20043367L (no) | Oralt farmasoytisk preparat | |
UA116334C2 (uk) | Тверді форми дозування бендамустину | |
NO20055631L (no) | Doseringsform inneholdende pantoprazol som aktiv ingrediens | |
BRPI0617655A2 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, ou um isômero óptico do mesmo, uso de um composto, e, formulação farmacêutica | |
CY1114163T1 (el) | Μεθοδοι χρησεως ανταγωνιστων αγγειοπιεσινης με παραγοντες χημειοθεραπειας ανθρακυκλινης για να μειωνεται καρδιοτοξικοτητα ή/και να βελτιωνεται επιβιωση | |
FR2983409B1 (fr) | Comprime susceptible de lutter contre le detournement par voie injectable | |
MX2022013984A (es) | Inhibidores de cinasa 7 relacionada con el gen nunca en mitosis a (nek7). | |
WO2005120518A3 (en) | Use of atp analogues for treatment of cardiovascular diseases | |
SE0401655D0 (sv) | New compounds | |
WO2004098577A3 (en) | Dosage form containing (s)-pantoprazole as active ingredient | |
WO2008057464A3 (en) | Compositions and methods for improving the bioavailability of liothyronine | |
MX2023011464A (es) | Inhibidores de la cinasa relacionada con el gen nunca en mitosis a 7 (nek7). | |
NO20064196L (no) | Utvortes preparat for behandling av smertefulle hudskader | |
NO20065074L (no) | Nye orale formuleringer av ospemifen. | |
NO20054319L (no) | Neovaskulaseringspromoter | |
PH12019501607A1 (en) | Tapentadol nasal composition |